BMJ Open (Apr 2016)

Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study

  • Ole Mogensen,
  • Mette Ørskov,
  • Maria Iachina,
  • Rikke Guldberg,
  • Bente Mertz Nørgård

DOI
https://doi.org/10.1136/bmjopen-2015-010123
Journal volume & issue
Vol. 6, no. 4

Abstract

Read online

Objectives To identify predictors of mortality within 1 year after primary surgery for ovarian cancer.Design Prospective nationwide cohort study from 1 January 2005 to 31 December 2012.Setting Evaluation of data from the Danish Gynaecology Cancer Database and the Danish Civil Registration System.Participants 2654 women who underwent surgery due to a diagnosis of primary ovarian cancer.Outcome measures Overall survival and predictors of mortality within 0–180 and 181–360 days after the primary surgery. Examined predictors were age, preoperative American Society of Anesthesiologists (ASA) score, body mass index (BMI), International Federation of Gynaecology and Obstetrics (FIGO) stage, residual tumour tissue after surgery, perioperative blood transfusion and calendar year of surgery.Results The overall 1-year survival was 84%. Within 0–180 days after surgery, the 3 most important predictors of mortality from the multivariable model were residual tumour tissue >2 cm versus no residual tumour (HR=4.58 (95% CI 3.20 to 6.59)), residual tumour tissue ≤2 cm versus no residual tumour (HR=2.50 (95% CI 1.63 to 3.82)) and age >64 years versus age ≤64 years (HR=2.33 (95% CI 1.69 to 3.21)). Within 181–360 days after surgery, FIGO stages III–IV versus I–II (HR=2.81 (95% CI 1.75 to 4.50)), BMI<18.5 vs 18.5–25 kg/m2 (HR=2.08 (95% CI 1.18 to 3.66)) and residual tumour tissue >2 cm versus no residual tumour (HR=1.84 (95% CI 1.25 to 2.70)) were the 3 most important predictors.Conclusions The most important predictors of mortality within 1 year after surgery were residual tumour tissue (0–180 days after surgery) and advanced FIGO stage (181–360 days after surgery). However, our results suggest that the surgeon should not just aim at radical surgery, but also pay special attention to comorbidity, nutritional state, age >64 years and the need for perioperative blood transfusion.